Diabetes, High BMI, Previous Metformin Common in Teens With Rx for GLP-1 RAs
By Lori Solomon HealthDay Reporter
WEDNESDAY, Oct. 16, 2024 -- Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have comorbid type 2 diabetes, high body mass index, and a previous metformin prescription, according to a research letter published online Oct. 16 in JAMA Network Open.
Margaret G. Miller, from Case Western Reserve University in Cleveland, and colleagues characterized patient demographics and the prevalence of comorbid conditions among 11,380 matched patients (aged 10 to 17 years) who received or did not receive a first prescription for a GLP-1 RA during visits from 2019 to 2023.
The researchers found that patients prescribed GLP-1 RAs were more commonly female (60.4 percent; P < 0.001), Black or African American (27.9 percent; P < 0.001) and Hispanic or Latinx individuals (25.3 percent; P < 0.001), and less commonly White individuals (46.0 percent; P < 0.001). Among patients receiving GLP-1 RAs, preexisting International Statistical Classification of Diseases and Related Health Problems, Tenth Revision encounter diagnosis codes of type 2 diabetes (46.2 percent), metabolic syndrome (16.0 percent), and type 1 diabetes (18.6 percent) were more common than among controls. Body mass index ≥95th percentile was more common among patients receiving a GLP-1 RA than those who did not (87.1 versus 32.9 percent). Two-thirds of patients receiving a GLP-1 RA prescription had a prior prescription for insulin, metformin, or orlistat.
“A deep understanding of the long-term impacts (i.e., physical, mental, sociocultural, etc.) of GLP-1 RAs on preadolescent and adolescent patients is crucial to better inform prescription practices and is an important direction for future studies,” the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
High Metabolic Syndrome Severity Linked to Development of CKD
FRIDAY, Aug. 15, 2025 -- High metabolic syndrome (MetS) severity, expressed by the continuous metabolic syndrome severity score (cMetS-S), is associated with development of...
26.5 Percent of Adults With Diabetes Used GLP-1 RA Injectables in 2024
THURSDAY, Aug. 14, 2025 -- In 2024, 26.5 percent of adults with diagnosed diabetes used glucagon-like peptide 1 receptor agonist (GLP-1 RA) injectables, according to an August...
2009 to 2023 Saw Increase in Use of Technology, Glycemic Control in Type 1 Diabetes
THURSDAY, Aug. 14, 2025 -- From 2009 to 2023, there was an increase in use of diabetes technology and in glycemic control among youths and adults with type 1 diabetes (T1D)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.